CORPORATE INFORMATION
Blue Sail / Biosensors Intl. enters the Structural Heart business and welcomes NVT in the group
Morges 9 June 2020
Biosensors International Group to appoint Prof Keith Oldroyd as Chief Medical Officer
Morges 2 June 2020
Biosensors International Announces Japanese PMDA Approval for BioFreedom™ Ultra and US FDA Approval for BioFreedom™ Biolimus A9™ Coated Polymer Free Coronary Stent Systems
Morges 21 April 2022
Biosensors International Group Ltd, announces CE Mark Approval for Biolimus A9™ Coated Cobalt Chromium Coronary Stent System BioFreedom™ Ultra
Morges 19 October 2020
Biosensors International Announces Enrollment of First Patient in Pivotal Trial of New Coronary Microcatheter - "BIOMICS"
Morges 5th April 2022
Biosensors International Announces Enrollment of First Patient in the RISE™ SC study
Morges 4th February 2022
Biosensors announces primary endpoint data release of the new US pivotal BioFreedom Trial – “LEADERS FREE II”
San Diego 22 September 2018
Biosensors Announces Enrollment of First Patient in New Pivotal Drug Coated Balloon Trial
Morges 11 August 2020